logo
  

Alnylam Pharmaceuticals Inc. Q2 adjusted earnings Beat Estimates

Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):

-Earnings: -$189.56 million in Q2 vs. -$179.23 million in the same period last year.
-EPS: -$1.61 in Q2 vs. -$1.56 in the same period last year.
-Excluding items, Alnylam Pharmaceuticals Inc. reported adjusted earnings of -$153.05 million or -$1.30 per share for the period.
-Analysts projected -$1.60 per share
-Revenue: $220.55 million in Q2 vs. $103.96 million in the same period last year.

-Guidance:
Full year revenue guidance: $640 - $665 Mln

For comments and feedback contact: editorial@rttnews.com

Follow RTT